Recent Updates
Recently added Catalysts
AQST Positive Sentiment

Aquestive Therapeutics to Present at the Piper Sandler 38th Annual Healthcare Conference

Key Takeaway: Aquestive Therapeutics will participate in the Piper Sandler 38th Annual Healthcare Conference from December 1-3, 2026, in New York City. CEO Daniel Barber is scheduled to present on December 2 at 10:30 am ET. The company will also host one-on-one meetings with investors that day.

Market Sentiment Analysis

POSITIVE FACTORS

  • Aquestive will present at a major healthcare conference.
  • The company is advancing innovative medicines.
  • Management will engage in one-on-one meetings with investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+34%
120-day peak, hindsight
Typical move
19.8%
average across 6 past catalysts
Cash runway
~38 mo
Minimal dilution risk
Lead asset
DESF
Phase 2 · Allergic Reaction

Full Press Release Details

WARREN, N.J., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science, announced today that the management team will participate in the Piper Sandler 38th Annual Healthcare Conference December 1-3, 2026, in New York City.
Aquestive President and CEO Daniel Barber will be presenting on Wednesday, December 2, 2026, at 10:30 am ET. The Company will also be hosting one-on-ones with investors that day.
A webcast of the presentation will be available under the “Events and Presentations” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit investors.aquestive.com.
About Aquestive Therapeutics Aquestive is a biopharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science. The worldwide leader in delivering trusted, quality medications on oral film, Aquestive develops proprietary pharmaceutical products and operates U.S.-based manufacturing facilities in Indiana, with its headquarters in New Jersey. The Company is the exclusive manufacturer of four commercialized products marketed by its licensees across six continents using proprietary, best-in-class technologies like PharmFilm®. Aquestive’s AdrenaVerse™ platform contains a library of more than 20 epinephrine prodrugs enabling the pursuit of various potential allergy and dermatological indications. The Company is advancing Anaphylm™ (dibutepinephrine) sublingual film for the treatment of severe allergic reactions, including anaphylaxis, and AQST-108 (epinephrine) topical gel for various potential dermatological conditions. For more information, visit Aquestive.com and follow us on LinkedIn.
Forward-Looking Statement
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the advancement and related timing of our product candidates, including Anaphylm™ (dibutepinephrine) sublingual film and AQST-108 (epinephrine prodrug) topical gel, through clinical development and approval by the U.S. Food and Drug Administration (FDA) for the respective targeted indications. These forward-looking statements are based on the Company’s current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of its product development activities and clinical trials, including relating to Anaphylm and AQST-108, and other risks and uncertainties affecting the Company described in the “Risk Factors” section and in other sections included in its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law. PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc.

Frequently Asked Questions

When will Aquestive present at the conference?

Aquestive will present on December 2, 2026, at 10:30 am ET.

Where is the Piper Sandler conference held?

The conference will take place in New York City.

Who will present for Aquestive Therapeutics?

CEO Daniel Barber will lead the presentation.

Will there be investor meetings?

Yes, the company will host one-on-one meetings with investors.

Last updated: Nov 18, 2026